November 6, 2014
The Pharmaceuticals and Medical Devices Agency (PMDA) said on October 31 that Alzheimer’s disease treatment Reminyl (galantamine) is now under review for the potential risk of acute generalized exanthematous pustulosis. The Ministry of Health, Labor and Welfare might order the...read more